Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease and Mutational Status Prior to and after SCT for Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Heike Pfeifer, MD, Sylvia Wystub, PhD, Barbara Wassmann, MD, Patrick Brueck, MD, Nicola Goekbuget, MD, Hubert Serve, MD, PhD, Dieter Hoelzer, MD, PhD, Oliver G Ottmann, MD

Blood (2008) 112 (11): 702.

https://doi.org/10.1182/blood.V112.11.702.702

Published: 2008

Journal Articles

More Rapid Outgrowth Kinetics of BCR-ABL Mutations in Advanced Versus Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Clinical-Translational Evidence for a Contributory Role of Non-Mutational Resistance Mechanisms.

Heike Pfeifer, MD, Barbara Wassmann, MD, Silvia Wystub, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Hubert Serve, MD, Dieter Hoelzer, MD, Oliver Ottmann, MD

Blood (2007) 110 (11): 10.

https://doi.org/10.1182/blood.V110.11.10.10

Published: 2007

Journal Articles

Treatment Outcome with Imatinib-Based Maintenance Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

Heike Pfeifer, MD, Barbara Wassmann, MD, Sylvia Wystub, MD, Lydia Wunderle, MD, Joerg Chromik, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Anja Binckebanck, Dieter Hoelzer, MD, Oliver Ottmann, MD

Blood (2007) 110 (11): 2817.

https://doi.org/10.1182/blood.V110.11.2817.2817

Published: 2007

Journal Articles

Long Term Outcome of Patients with Steroid Refractory Acute Intestinal Graft Versus Host Disease after Treatment with Pentostatin.

Stefan A. Klein, MD, Sabine Mousset, MD, Gesine Bug, MD, Barbara Waßmann, MD, Dieter Hoelzer, MD, Hans Martin, MD

Blood (2006) 108 (11): 2870.

https://doi.org/10.1182/blood.V108.11.2870.2870

Published: 2006

Journal Articles

Sustained Molecular Responses to Dasatanib (SPRYCEL®) in Patients with Philadelphia Chromosome-Positive (Ph(+)) Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase (LyBP) Chronic Myeloid Leukemia after Imatinib (IM) Failure: A Single-Center Experience.

Joerg Chromik, MD, Heike Pfeifer, MD, Lydia Wunderle, MD, Nadine Schoch, Barbara Wassmann, MD, Patrick Brueck, MD, Ashwin Gollerkeri, MD, Dieter Hoelzer, MD, PhD, Oliver G. Ottmann, MD

Blood (2006) 108 (11): 285.

https://doi.org/10.1182/blood.V108.11.285.285

Published: 2006

Journal Articles

Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).

Heike Pfeifer, MD, Barbara Wassmann, MD, Anna Pavlova, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Andreas Hochhaus, MD, Dieter Hoelzer, MD, PhD, Oliver Ottmann, MD

Blood (2006) 108 (11): 639.

https://doi.org/10.1182/blood.V108.11.639.639

Published: 2006

Journal Articles

A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns.

Heike Pfeifer, MD, Oliver G. Ottmann, MD, Nicola Goekbuget, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Aristoteles Giagounidis, MD, Michael Stelljes, MD, Andreas Hochhaus, MD, Harald Gschaidmeier, MD, Dieter Hoelzer, MD, Barbara Wassmann, MD

Blood (2005) 106 (11): 1824.

https://doi.org/10.1182/blood.V106.11.1824.1824

Published: 2005

Journal Articles

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

Heike Pfeifer, MD, Barbara Wassmann, MD, Anni Pavlova, MD, Martin Mueller, MD, Lydia Wunderle, MD, Patrick Brueck, MD, Johannes Oldenburg, MD, Andreas Hochhaus, MD, Harald Gschaidmeier, MD, Dieter Hoelzer, MD, PhD, Oliver G. Ottmann, MD

Blood (2005) 106 (11): 147.

https://doi.org/10.1182/blood.V106.11.147.147

Published: 2005

Journal Articles

Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL).

Dieter Hoelzer, MD, PhD, Nicola Goekbuget, MD, Joachim Beck, MD, Thomas Burmeister, MD, Aristoteles Giagounidis, MD, Axel Glasmacher, MD, Heike Pfeifer, MD, Harald Rieder, MD, Mathias Schmid, MD, Eckhard Thiel, MD, PhD, Barbara Wassmann, MD, Oliver Ottmann, MD, PhD

Blood (2004) 104 (11): 2732.

https://doi.org/10.1182/blood.V104.11.2732.2732

Published: 2004

Journal Articles

Imatinib Given Concurrently with Induction Chemotherapy Is Superior to Imatinib Subsequent to Induction and Consolidation in Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (PH+ALL).

Oliver G. Ottmann, MD, Barbara Wassmann, MD, Heike Pfeifer, MD, Nicola Goekbuget, MD, Gesine Bug, MD, Patrick Brueck, MD, Anja Binckebanck, Harald Gschaidmeier, MD, Dieter Hoelzer, MD

Blood (2004) 104 (11): 685.

https://doi.org/10.1182/blood.V104.11.685.685

Published: 2004

NARROW

Minimal Residual Disease and Mutational Status Prior to and after SCT for Patients with Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

More Rapid Outgrowth Kinetics of BCR-ABL Mutations in Advanced Versus Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): Clinical-Translational Evidence for a Contributory Role of Non-Mutational Resistance Mechanisms.

Treatment Outcome with Imatinib-Based Maintenance Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukaemia (Ph+ALL) Ineligible for Allogeneic Stem Cell Transplantation (SCT).

Long Term Outcome of Patients with Steroid Refractory Acute Intestinal Graft Versus Host Disease after Treatment with Pentostatin.

Sustained Molecular Responses to Dasatanib (SPRYCEL®) in Patients with Philadelphia Chromosome-Positive (Ph(+)) Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase (LyBP) Chronic Myeloid Leukemia after Imatinib (IM) Failure: A Single-Center Experience.

Bcr-Abl Tyrosine Kinase Domain Mutations Both Pre-Exist and Develop during Imatinib Treatment and Are Responsible for Resistance in Patients with Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).

A Randomized Phase II Study of Single-Agent Imatinib Versus Chemotherapy Therapy in Elderly Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Including Analysis of Resistance Patterns.

Pattern and Evolution of BCR-ABL Kinase Domain Mutations in Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Developing Resistance to Imatinib.

Subtype Adjusted Therapy Improves Outcome of Elderly Patients with Acute Lymphoblastic Leukemia (ALL).

Imatinib Given Concurrently with Induction Chemotherapy Is Superior to Imatinib Subsequent to Induction and Consolidation in Newly Diagnosed Philadelphia-Positive Acute Lymphoblastic Leukemia (PH+ALL).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only